Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

445 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Teprotumumab for Thyroid-Associated Ophthalmopathy.
Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS. Smith TJ, et al. Among authors: salvi m. N Engl J Med. 2017 May 4;376(18):1748-1761. doi: 10.1056/NEJMoa1614949. N Engl J Med. 2017. PMID: 28467880 Free PMC article. Clinical Trial.
Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.
Antonelli A, Ferrari SM, Fallahi P, Piaggi S, Paolicchi A, Franceschini SS, Salvi M, Ferrannini E. Antonelli A, et al. Among authors: salvi m. Metabolism. 2011 Feb;60(2):277-83. doi: 10.1016/j.metabol.2010.02.002. Epub 2010 Mar 6. Metabolism. 2011. PMID: 20206950
Immunotherapy for Graves' ophthalmopathy.
Salvi M. Salvi M. Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):409-14. doi: 10.1097/MED.0000000000000097. Curr Opin Endocrinol Diabetes Obes. 2014. PMID: 25105999 Review.
PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.
Perros P, Žarković M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, Boschi A, Bournaud C, Brix TH, Covelli D, Ćirić S, Daumerie C, Eckstein A, Fichter N, Führer D, Hegedüs L, Kahaly GJ, Konuk O, Lareida J, Lazarus J, Leo M, Mathiopoulou L, Menconi F, Morris D, Okosieme O, Orgiazzi J, Pitz S, Salvi M, Vardanian-Vartin C, Wiersinga W, Bernard M, Clarke L, Currò N, Dayan C, Dickinson J, Knežević M, Lane C, Marcocci C, Marinò M, Möller L, Nardi M, Neoh C, Pearce S, von Arx G, Törüner FB. Perros P, et al. Among authors: salvi m. Br J Ophthalmol. 2015 Nov;99(11):1531-5. doi: 10.1136/bjophthalmol-2015-306733. Epub 2015 May 7. Br J Ophthalmol. 2015. PMID: 25953846
Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement.
Perros P, Dayan CM, Dickinson AJ, Ezra DG, Hickey JL, Hintschisch C, Kahaly G, Lazarus JH, Ludgate M, Bartès B, MacEwen CJ, Mitchell AL, Morris D, O'Connor N, Pearce SH, Rose GE, Salvi M, Wiersinga WM, Williamson A; Thyroid Eye Disease Amsterdam Declaration Implementation Group UK; European Group on Graves’ Orbitopathy. Perros P, et al. Among authors: salvi m. Thyroid. 2015 Nov;25(11):1181-4. doi: 10.1089/thy.2015.0222. Epub 2015 Oct 14. Thyroid. 2015. PMID: 26359308 Free PMC article. No abstract available.
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.
Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM; European Group on Graves' Orbitopathy (EUGOGO). Bartalena L, et al. Among authors: salvi m. Eur Thyroid J. 2016 Mar;5(1):9-26. doi: 10.1159/000443828. Epub 2016 Mar 2. Eur Thyroid J. 2016. PMID: 27099835 Free PMC article.
445 results